NCT07605676 Acupoint TENS vs Resistance Training for Iron Deficiency Anemia
| NCT ID | NCT07605676 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Cairo University |
| Condition | Iron Deficiency Anemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-01-15 |
| Primary Completion | 2026-08-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 60 participants in total. It began in 2026-01-15 with a primary completion date of 2026-08-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The current study is designed to compare between the effect of transcutaneous electrical acupoint stimulation and resistance exercises on hemoglobin level in women with iron deficiency anemia.The design of this study will be a randomized controlled trial (RCT) pretest post-test assessment.Sixty women diagnosed with iron deficiency anemia will be recruited in this study from Kafrelshiekh University Hospital, Kafrelshiekh Governorate, Egypt. Their ages will be ranged from 20 to 30 years old, and they will be randomly divided into three equal (n= 20) groups. Change in hemoglobin concentration (g/dL) after the intervention period and changes in RBC count, MCV, MCH, RDW, serum ferritin, fatigue level, and functional exercise capacity after treatment will be measured.
Eligibility Criteria
Inclusion Criteria: * Sixty women diagnosed with iron deficiency anemia within ≤6 months. * Their hemoglobin concentrations ranging from 8.0 to 10.9 g/dL that classified as moderate anemia in accordance with the World Health Organization (WHO) criteria. * The iron deficiency anemia resulted from the heavy monthly bleeding of menstrual cycle as reported by the women. * Their age will be ranged from 20 and 30 years old. * Their BMI will be ranged from 18.5 to 24.9 kg/m². * They will have the same level of functional capacity assessed by 6-minute walking test. * They will be receiving the same medical treatment programme. Exclusion Criteria: * Other causes of anemia (e.g., hemolytic anemia, anemia of chronic disease, megaloblastic anemia, thalassemia, or sickle cell disease). * Severe anemia (hemoglobin \< 8.0 g/dL) * History of chronic kidney disease, liver disease, or malignancy. * Current pregnancy or lactation, due to altered iron metabolism and hemoglobin thresholds. * Recent blood transfusion or iron therapy (oral or intravenous) within the past 3 months. * Use of hematopoietic agents (e.g., erythropoietin). * Acute infection or inflammatory conditions at the time of enrollment. * Inability or unwillingness to provide informed consent or comply with study procedures. * Previous participation in complementary treatments/research within the last six months.
Contact & Investigator
Dina Ebrahim Mohamed Aboshady, BSc PT
STUDY DIRECTOR
Faculty of Physical Therapy, Kafrelsheikh University
Frequently Asked Questions
Who can join the NCT07605676 clinical trial?
This trial is open to female participants only, aged 20 Years or older, up to 30 Years, studying Iron Deficiency Anemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07605676 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07605676 currently recruiting?
Yes, NCT07605676 is actively recruiting participants. Contact the research team at dinaaboshady2020@gmail.com for enrollment information.
Where is the NCT07605676 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07605676 clinical trial?
NCT07605676 is sponsored by Cairo University. The principal investigator is Dina Ebrahim Mohamed Aboshady, BSc PT at Faculty of Physical Therapy, Kafrelsheikh University. The trial plans to enroll 60 participants.